Highlights

  • BCAL Diagnostics (ASX:BDX) traded at AUD 0.070, up 34.62% during the afternoon Trading session on 26 August 2026.
  • The company acquired 18.75 million Genetic Signatures shares for $1.5m at $0.08 per share.
  • BCAL’s total holding in Genetic Signatures increased to approximately 18.46%.
  • The Investment aims to broaden BCAL’s diagnostic platform into infectious disease applications.
  • BCAL continues commercial activities across its BREASTESTplus and Avantect testing portfolio.

BCAL Diagnostics Limited (ASX:BDX) has increased its investment in Genetic Signatures Ltd (ASX:GSS), lifting its total ownership interest to approximately 18.46% as part of a strategy to broaden its diagnostic platform.

The company traded at AUD 0.070, up 34.62% during the afternoon trading session on 26 August 2026. Over the past year, BCAL Diagnostics’ share price has increased 16.67%.

The healthcare company acquired an additional 18.75 million shares in Genetic Signatures for $1.5m in cash, strengthening its exposure to molecular diagnostics technology and potential future opportunities across infectious disease testing.

Investment Details

BCAL acquired approximately 8.25% of Genetic Signatures through the purchase of 18.75 million shares at $0.08 per share.

Following the transaction, BCAL’s total holding increased to 41,923,644 shares, representing approximately 18.46% of Genetic Signatures.

The company said the investment reflects its interest in using Genetic Signatures’ technology to broaden its own diagnostic platform and create additional growth opportunities.

Strategic Rationale

BCAL considers Genetic Signatures a complementary molecular diagnostics company.

The investment is aimed at expanding BCAL’s diagnostic capabilities beyond its existing focus areas by gaining exposure to infectious disease applications.

The company said the combination of complementary technical capabilities, laboratory infrastructure and potential distribution opportunities could support future platform expansion.

Genetic Signatures develops molecular diagnostic solutions based on its proprietary 3base® technology platform.

Its EasyScreen range of real-time PCR-based products is designed for routine detection of infectious diseases across hospitals and pathology laboratories.

BCAL Diagnostics Platform

BCAL Diagnostics focuses on early cancer detection technologies.

The company’s first commercial test, BREASTESTplus, is designed as a rule-out test to support clinical evaluation of breast disease in women with dense breasts.

The non-invasive blood test is intended to be used alongside mammography to assist screening and diagnostic outcomes for breast health.

BCAL also holds an exclusive licence with ClearNote Health Inc. for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests across Australia and New Zealand.

Management Commentary

BCAL Non-Executive Chair Jayne Shaw said the increased investment reflected the company’s view of Genetic Signatures’ complementary diagnostics technology and the strategic opportunities it may provide.

BCAL CEO Anne-Louise Arnett said the company sees strategic value in Genetic Signatures’ technology and believes the investment could support long-term value creation.

Ms Arnett added that BCAL remains focused on its existing operations and driving commercial adoption of its BREASTESTplus and Avantect Pancreatic and Ovarian test portfolio.

Genetic Signatures Technology

Genetic Signatures is a specialist molecular diagnostics company focused on developing and commercialising its proprietary 3base® platform technology.

The company’s EasyScreen products use real-time PCR technology to enable hospitals and pathology laboratories to screen for a broad range of infectious pathogens.

BCAL said the technology provides a complementary opportunity as it continues developing its broader diagnostic platform.

Future Focus

BCAL’s increased investment provides the company with exposure to Genetic Signatures while maintaining its focus on commercialising its existing diagnostic products.

The company continues advancing its early cancer detection portfolio while exploring opportunities to expand its diagnostic capabilities.

The investment follows BCAL’s broader strategy of building a diversified healthcare diagnostics platform.

Investor Takeaway

BCAL Diagnostics’ increased stake in Genetic Signatures represents a strategic investment aimed at broadening its diagnostic technology exposure. The transaction increases BCAL’s holding to 18.46% and provides access to molecular diagnostics capabilities focused on infectious disease testing. Investors may continue watching the development of BCAL’s cancer detection portfolio, Genetic Signatures’ technology progress and any future collaboration opportunities between the businesses.